Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania

Domeikienė, Auksė; Vaivadaitė, Justina; Ivanaūskienė, Rugile; Padaiga, Žilvinas

doi:10.1016/j.medici.2014.05.007

Cited by 28 publications

(27 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A correlation between the number of complications and the increase of average annual cost per patient was observed, accounting for up to 1588.98 EUR. [30] The results from our study are similar, demonstrating that diabetes is a costly disease when complications develop. In Bulgaria, the costs due to complications are the leading ones, especially when patients should be hospitalized.…”

Section: Sensitivity Analysissupporting

confidence: 76%

See 1 more Smart Citation

Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria

Dimitrova

Doneva

Valov³

et al. 2015

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

The objective of this study was to evaluate the cost of hospitalizations due to micro-and macrovascular complications in an observed cohort of 433 patients with diabetes. A six-month combined retrospective and prospective observational study was performed. The patients were separated into two groups depending on the type of diabetes and further into subgroups depending on the reason for hospitalization. The total costs for each subgroup were calculated and compared to the total costs of treatment for the observed period. In the type 2 diabetes group (n D 255), there were 128 people with microvascular complications and 215 ones with macrovascular complications, whereas in the type 1 diabetes group, there were only 70 people out of 178 with microvascular complications and 72 ones with macrovascular complications. The total cost of hospitalizations in the type 2 diabetes group was 34 469.76 EUR with the following reported reasons for hospitalizations: poor control of diabetes (45%), microvascular complications (23%) and macrovascular complications (31%). In the type 1 diabetes group, the total hospitalizations cost was equal to 15 319.33 EUR with the following split: 59% due to poor control of diabetes, 22% due to microvascular complications and 19% due to macrovascular complications. Thus, type 2 diabetes is more costly than type 1 when hospitalizations occur. Type 2 diabetes is associated with higher cost of macrovascular complications than of microvascular ones probably due to high hypertension prevalence. Costs are paid by the health insurance fund and the differences need to be systematically revealed.

show abstract

Section: Sensitivity Analysissupporting

confidence: 76%

“…[30] The cost included pharmacotherapy and diabetes supplies. The majority of patients were diagnosed with at least one diabetes-related chronic complication.…”

Section: Sensitivity Analysismentioning

confidence: 99%

Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria

Dimitrova

Doneva

Valov³

et al. 2015

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

show abstract

“…The high prevalence of type 2 diabetes mellitus in developed countries substantially increases costs. A study conducted in Lithuania reported that the average cost for a regular patient in 2011 was €156.14, while the average cost for a diabetic patient was €448.34; the costs of medication and medical care weighing on this difference …”

Section: Introductionmentioning

confidence: 99%

Impact of type 2 diabetes mellitus and physical activity on medication costs in older adults

Koyama

Monteiro

Lemes

et al. 2019

Health Planning & Management

View full text Add to dashboard Cite

Summary Introduction The high prevalence of diabetes mellitus leads to high costs of medication for treatment and the practice of physical activity, as well as reducing the risks of diabetes mellitus is able to substantially mitigate costs. To investigate the impact of diabetes mellitus on costs of medication and identify whether physical activity can influence the relationship between diabetes mellitus and costs of medication. Methods The sample consisted of adults enrolled in five basic healthcare units. The presence of diabetes mellitus and habitual physical activity were assessed by a questionnaire, the quantity of medication used was evaluated according to the medical records, and medication costs, through receipts. Findings Individuals with diabetes mellitus from baseline presented higher body weight (P value = .001) and lower levels of physical activity (P value = .014). The presence of diabetes mellitus was positively related to costs of medication for diseases of the circulatory system (β = 4.89), endocrine, nutritional, and metabolic diseases (β = 109.72), and total costs of medication (β = 113.41). The impact of diabetes mellitus was attenuated by physical activity. Conclusion It was identified that diabetes mellitus has a significant impact on public costs with medication, and physical activity was effective in reducing health costs independently of diabetes mellitus by less than 1%.

show abstract

“…The American Diabetes Association (ADA) calculated that people with diabetes have healthcare expenditure 2.3 times higher than that for the same population without diabetes . While the care for people with diabetes who experience macro‐ and microvascular complications is particularly costly to the healthcare system; metabolic complications may explain ~11% of the extra costs of the disease . In the Netherlands, the total economic burden of diabetes was calculated to be €6.8 bn in 2016 .…”

Section: Introductionmentioning

confidence: 99%

Clinical effectiveness of liraglutide vs basal insulin in a real‐world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes

Overbeek

Heintjes

Huisman³

et al. 2018

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimsTo compare real‐world antidiabetic treatment outcomes over 12 months in obese people with type 2 diabetes mellitus (T2DM) who previously received oral antidiabetic therapy and then initiated a first injectable therapy with liraglutide or basal insulin.Patients and methodsThis was a retrospective, propensity score‐matched, longitudinal cohort study using real‐world data (January 2010 to December 2015) from the Dutch PHARMO Database Network. Adult obese (body mass index [BMI] ≥35 kg/m2) patients with T2DM with ≥2 dispensing dates for liraglutide or basal insulin supported oral therapy (BOT) were selected. The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline during 12 months of follow‐up. The secondary endpoints were the changes in weight, BMI and cardiovascular risk factors from baseline. Clinical data were analysed using descriptive statistics and compared using mixed models for repeated measures.ResultsObese patients with T2DM (N = 1157) in each treatment group were matched (liraglutide cohort, n = 544; BOT cohort, n = 613). From 3 months onwards, glycaemic control improved in both cohorts but improved significantly more with liraglutide than with BOT (12 months: −12.2 mmol/mol vs −8.8 mmol/mol; P = .0053). In addition, weight and BMI were significantly lower for treatments with liraglutide vs BOT (12 months: −6.0 kg vs −1.6 kg and − 2.1 kg/m2 vs −0.5 kg/m2, respectively; P < .0001 for both). No significant differences were seen in changes in cardiovascular risk factors.ConclusionsThe results of this real‐world study in matched obese patients with T2DM showed that liraglutide was more effective than BOT for HbA1c control and weight/BMI reductions. Patients were more likely to maintain glycaemic control over time after initiating liraglutide than after initiating BOT.

show abstract

Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania

Cited by 28 publications

References 13 publications

Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria

Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria

Impact of type 2 diabetes mellitus and physical activity on medication costs in older adults

Clinical effectiveness of liraglutide vs basal insulin in a real‐world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes

Contact Info

Product

Resources

About